Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.7874 |
Intermediate Similarity |
NPD5603 |
Clinical (unspecified phase) |
0.774 |
Intermediate Similarity |
NPD6654 |
Clinical (unspecified phase) |
0.766 |
Intermediate Similarity |
NPD6321 |
Discontinued |
0.7473 |
Intermediate Similarity |
NPD6021 |
Clinical (unspecified phase) |
0.7368 |
Intermediate Similarity |
NPD1880 |
Phase 3 |
0.7351 |
Intermediate Similarity |
NPD6608 |
Clinical (unspecified phase) |
0.7345 |
Intermediate Similarity |
NPD5183 |
Approved |
0.7345 |
Intermediate Similarity |
NPD5186 |
Approved |
0.7253 |
Intermediate Similarity |
NPD6293 |
Clinical (unspecified phase) |
0.724 |
Intermediate Similarity |
NPD4496 |
Clinical (unspecified phase) |
0.7238 |
Intermediate Similarity |
NPD1212 |
Approved |
0.7204 |
Intermediate Similarity |
NPD4515 |
Suspended |
0.7179 |
Intermediate Similarity |
NPD4465 |
Phase 2 |
0.7179 |
Intermediate Similarity |
NPD4467 |
Phase 2 |
0.7165 |
Intermediate Similarity |
NPD7627 |
Approved |
0.7165 |
Intermediate Similarity |
NPD7626 |
Approved |
0.7143 |
Intermediate Similarity |
NPD5294 |
Clinical (unspecified phase) |
0.7128 |
Intermediate Similarity |
NPD5896 |
Clinical (unspecified phase) |
0.7128 |
Intermediate Similarity |
NPD7064 |
Clinical (unspecified phase) |
0.7083 |
Intermediate Similarity |
NPD5515 |
Phase 2 |
0.705 |
Intermediate Similarity |
NPD6567 |
Clinical (unspecified phase) |
0.703 |
Intermediate Similarity |
NPD5293 |
Phase 2 |
0.7029 |
Intermediate Similarity |
NPD4201 |
Clinical (unspecified phase) |
0.702 |
Intermediate Similarity |
NPD7043 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD7126 |
Discontinued |
0.7 |
Intermediate Similarity |
NPD5262 |
Discontinued |
0.6959 |
Remote Similarity |
NPD5071 |
Phase 2 |
0.6959 |
Remote Similarity |
NPD160 |
Clinical (unspecified phase) |
0.6954 |
Remote Similarity |
NPD6478 |
Clinical (unspecified phase) |
0.6946 |
Remote Similarity |
NPD822 |
Approved |
0.6939 |
Remote Similarity |
NPD7566 |
Clinical (unspecified phase) |
0.6927 |
Remote Similarity |
NPD6533 |
Clinical (unspecified phase) |
0.6919 |
Remote Similarity |
NPD5102 |
Clinical (unspecified phase) |
0.6919 |
Remote Similarity |
NPD4981 |
Phase 2 |
0.6902 |
Remote Similarity |
NPD4020 |
Clinical (unspecified phase) |
0.6885 |
Remote Similarity |
NPD2248 |
Approved |
0.6885 |
Remote Similarity |
NPD2246 |
Approved |
0.6868 |
Remote Similarity |
NPD5847 |
Phase 1 |
0.6865 |
Remote Similarity |
NPD3050 |
Clinical (unspecified phase) |
0.6854 |
Remote Similarity |
NPD2842 |
Clinical (unspecified phase) |
0.6837 |
Remote Similarity |
NPD6874 |
Approved |
0.6828 |
Remote Similarity |
NPD5900 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD6357 |
Discontinued |
0.6813 |
Remote Similarity |
NPD6457 |
Approved |
0.6813 |
Remote Similarity |
NPD2249 |
Approved |
0.6813 |
Remote Similarity |
NPD2247 |
Approved |
0.6807 |
Remote Similarity |
NPD3142 |
Approved |
0.6807 |
Remote Similarity |
NPD3140 |
Approved |
0.6806 |
Remote Similarity |
NPD2542 |
Clinical (unspecified phase) |
0.6802 |
Remote Similarity |
NPD4491 |
Clinical (unspecified phase) |
0.6793 |
Remote Similarity |
NPD5997 |
Discontinued |
0.6789 |
Remote Similarity |
NPD3154 |
Approved |
0.6789 |
Remote Similarity |
NPD3153 |
Approved |
0.6786 |
Remote Similarity |
NPD743 |
Approved |
0.6784 |
Remote Similarity |
NPD5513 |
Phase 2 |
0.678 |
Remote Similarity |
NPD4679 |
Discontinued |
0.678 |
Remote Similarity |
NPD1337 |
Clinical (unspecified phase) |
0.6774 |
Remote Similarity |
NPD5521 |
Clinical (unspecified phase) |
0.6771 |
Remote Similarity |
NPD4259 |
Approved |
0.6771 |
Remote Similarity |
NPD4258 |
Approved |
0.6769 |
Remote Similarity |
NPD7880 |
Clinical (unspecified phase) |
0.6757 |
Remote Similarity |
NPD7449 |
Clinical (unspecified phase) |
0.6754 |
Remote Similarity |
NPD6393 |
Clinical (unspecified phase) |
0.6753 |
Remote Similarity |
NPD4539 |
Phase 1 |
0.6733 |
Remote Similarity |
NPD7467 |
Discontinued |
0.6733 |
Remote Similarity |
NPD6593 |
Clinical (unspecified phase) |
0.6721 |
Remote Similarity |
NPD2681 |
Approved |
0.6721 |
Remote Similarity |
NPD2680 |
Approved |
0.672 |
Remote Similarity |
NPD6645 |
Clinical (unspecified phase) |
0.6704 |
Remote Similarity |
NPD7317 |
Phase 3 |
0.6703 |
Remote Similarity |
NPD5858 |
Discontinued |
0.6698 |
Remote Similarity |
NPD7186 |
Phase 3 |
0.6684 |
Remote Similarity |
NPD4078 |
Clinical (unspecified phase) |
0.6684 |
Remote Similarity |
NPD3793 |
Phase 3 |
0.6682 |
Remote Similarity |
NPD3912 |
Discontinued |
0.6651 |
Remote Similarity |
NPD3441 |
Approved |
0.6651 |
Remote Similarity |
NPD3442 |
Approved |
0.6648 |
Remote Similarity |
NPD4205 |
Phase 3 |
0.6648 |
Remote Similarity |
NPD2366 |
Approved |
0.6633 |
Remote Similarity |
NPD6519 |
Phase 2 |
0.6633 |
Remote Similarity |
NPD5228 |
Phase 3 |
0.6632 |
Remote Similarity |
NPD5620 |
Clinical (unspecified phase) |
0.6632 |
Remote Similarity |
NPD6040 |
Clinical (unspecified phase) |
0.663 |
Remote Similarity |
NPD1012 |
Discontinued |
0.663 |
Remote Similarity |
NPD7318 |
Phase 3 |
0.6628 |
Remote Similarity |
NPD4598 |
Approved |
0.6628 |
Remote Similarity |
NPD4597 |
Approved |
0.6619 |
Remote Similarity |
NPD3437 |
Discontinued |
0.6615 |
Remote Similarity |
NPD4372 |
Phase 1 |
0.661 |
Remote Similarity |
NPD1670 |
Discontinued |
0.6605 |
Remote Similarity |
NPD1659 |
Phase 1 |
0.6599 |
Remote Similarity |
NPD3964 |
Approved |
0.6598 |
Remote Similarity |
NPD6136 |
Phase 2 |
0.6589 |
Remote Similarity |
NPD3899 |
Clinical (unspecified phase) |
0.6585 |
Remote Similarity |
NPD5860 |
Discontinued |
0.6578 |
Remote Similarity |
NPD5938 |
Phase 3 |
0.6575 |
Remote Similarity |
NPD6060 |
Clinical (unspecified phase) |
0.6573 |
Remote Similarity |
NPD1678 |
Clinical (unspecified phase) |
0.6568 |
Remote Similarity |
NPD2791 |
Discontinued |
0.6566 |
Remote Similarity |
NPD7238 |
Clinical (unspecified phase) |
0.6561 |
Remote Similarity |
NPD2425 |
Phase 1 |
0.6557 |
Remote Similarity |
NPD1309 |
Phase 2 |
0.6557 |
Remote Similarity |
NPD1307 |
Phase 2 |
0.655 |
Remote Similarity |
NPD7255 |
Clinical (unspecified phase) |
0.6544 |
Remote Similarity |
NPD7031 |
Phase 1 |
0.6543 |
Remote Similarity |
NPD4498 |
Clinical (unspecified phase) |
0.654 |
Remote Similarity |
NPD8479 |
Phase 2 |
0.6537 |
Remote Similarity |
NPD3874 |
Discontinued |
0.6526 |
Remote Similarity |
NPD5566 |
Clinical (unspecified phase) |
0.6526 |
Remote Similarity |
NPD6211 |
Clinical (unspecified phase) |
0.6524 |
Remote Similarity |
NPD6365 |
Clinical (unspecified phase) |
0.6522 |
Remote Similarity |
NPD7225 |
Discontinued |
0.6519 |
Remote Similarity |
NPD6279 |
Approved |
0.6519 |
Remote Similarity |
NPD6844 |
Discontinued |
0.6519 |
Remote Similarity |
NPD6280 |
Approved |
0.6513 |
Remote Similarity |
NPD5113 |
Approved |
0.6513 |
Remote Similarity |
NPD5114 |
Approved |
0.6513 |
Remote Similarity |
NPD5112 |
Approved |
0.6512 |
Remote Similarity |
NPD3391 |
Approved |
0.6508 |
Remote Similarity |
NPD3965 |
Phase 1 |
0.6508 |
Remote Similarity |
NPD5334 |
Clinical (unspecified phase) |
0.6507 |
Remote Similarity |
NPD5025 |
Approved |
0.6502 |
Remote Similarity |
NPD6250 |
Discontinued |
0.6497 |
Remote Similarity |
NPD2335 |
Discontinued |
0.6495 |
Remote Similarity |
NPD6247 |
Clinical (unspecified phase) |
0.6491 |
Remote Similarity |
NPD2670 |
Approved |
0.6488 |
Remote Similarity |
NPD2907 |
Approved |
0.6488 |
Remote Similarity |
NPD8027 |
Approved |
0.6488 |
Remote Similarity |
NPD2906 |
Approved |
0.6485 |
Remote Similarity |
NPD7316 |
Discontinued |
0.6485 |
Remote Similarity |
NPD6795 |
Clinical (unspecified phase) |
0.648 |
Remote Similarity |
NPD5525 |
Clinical (unspecified phase) |
0.648 |
Remote Similarity |
NPD5994 |
Discontinued |
0.6474 |
Remote Similarity |
NPD5441 |
Clinical (unspecified phase) |
0.6474 |
Remote Similarity |
NPD7753 |
Approved |
0.6474 |
Remote Similarity |
NPD7752 |
Approved |
0.6471 |
Remote Similarity |
NPD7607 |
Clinical (unspecified phase) |
0.6471 |
Remote Similarity |
NPD3507 |
Phase 2 |
0.6471 |
Remote Similarity |
NPD4130 |
Phase 3 |
0.6471 |
Remote Similarity |
NPD5601 |
Phase 2 |
0.6465 |
Remote Similarity |
NPD5640 |
Discontinued |
0.6462 |
Remote Similarity |
NPD7180 |
Phase 3 |
0.6459 |
Remote Similarity |
NPD7559 |
Phase 2 |
0.6458 |
Remote Similarity |
NPD7190 |
Clinical (unspecified phase) |
0.6457 |
Remote Similarity |
NPD2241 |
Approved |
0.6453 |
Remote Similarity |
NPD3170 |
Approved |
0.6453 |
Remote Similarity |
NPD3802 |
Phase 3 |
0.6448 |
Remote Similarity |
NPD5616 |
Clinical (unspecified phase) |
0.6446 |
Remote Similarity |
NPD850 |
Approved |
0.6446 |
Remote Similarity |
NPD848 |
Approved |
0.6446 |
Remote Similarity |
NPD849 |
Approved |
0.6441 |
Remote Similarity |
NPD7560 |
Approved |
0.6429 |
Remote Similarity |
NPD1769 |
Discontinued |
0.6429 |
Remote Similarity |
NPD4081 |
Clinical (unspecified phase) |
0.6425 |
Remote Similarity |
NPD3613 |
Discontinued |
0.6425 |
Remote Similarity |
NPD4997 |
Clinical (unspecified phase) |
0.6425 |
Remote Similarity |
NPD3627 |
Approved |
0.6425 |
Remote Similarity |
NPD8330 |
Clinical (unspecified phase) |
0.6422 |
Remote Similarity |
NPD6644 |
Discontinued |
0.6421 |
Remote Similarity |
NPD5600 |
Discontinued |
0.6418 |
Remote Similarity |
NPD7810 |
Phase 3 |
0.6418 |
Remote Similarity |
NPD2778 |
Approved |
0.6418 |
Remote Similarity |
NPD7811 |
Phase 3 |
0.6411 |
Remote Similarity |
NPD3945 |
Discontinued |
0.641 |
Remote Similarity |
NPD4084 |
Clinical (unspecified phase) |
0.6408 |
Remote Similarity |
NPD4082 |
Approved |
0.6406 |
Remote Similarity |
NPD4204 |
Approved |
0.6406 |
Remote Similarity |
NPD4203 |
Approved |
0.6402 |
Remote Similarity |
NPD3446 |
Phase 1 |
0.6402 |
Remote Similarity |
NPD2359 |
Approved |
0.6402 |
Remote Similarity |
NPD6824 |
Clinical (unspecified phase) |
0.64 |
Remote Similarity |
NPD6621 |
Clinical (unspecified phase) |
0.64 |
Remote Similarity |
NPD4430 |
Phase 2 |
0.6398 |
Remote Similarity |
NPD6719 |
Approved |
0.6398 |
Remote Similarity |
NPD2162 |
Clinical (unspecified phase) |
0.6398 |
Remote Similarity |
NPD3940 |
Clinical (unspecified phase) |
0.6396 |
Remote Similarity |
NPD3808 |
Clinical (unspecified phase) |
0.6389 |
Remote Similarity |
NPD814 |
Clinical (unspecified phase) |
0.6387 |
Remote Similarity |
NPD3239 |
Clinical (unspecified phase) |
0.6385 |
Remote Similarity |
NPD3783 |
Clinical (unspecified phase) |
0.6384 |
Remote Similarity |
NPD6884 |
Clinical (unspecified phase) |
0.6376 |
Remote Similarity |
NPD4952 |
Phase 3 |
0.6376 |
Remote Similarity |
NPD7589 |
Clinical (unspecified phase) |
0.6368 |
Remote Similarity |
NPD5940 |
Clinical (unspecified phase) |
0.6368 |
Remote Similarity |
NPD7893 |
Clinical (unspecified phase) |
0.6368 |
Remote Similarity |
NPD1544 |
Phase 1 |
0.6368 |
Remote Similarity |
NPD2361 |
Approved |
0.6364 |
Remote Similarity |
NPD3511 |
Discontinued |
0.6364 |
Remote Similarity |
NPD6379 |
Discontinued |
0.6364 |
Remote Similarity |
NPD4986 |
Clinical (unspecified phase) |
0.6364 |
Remote Similarity |
NPD3479 |
Discontinued |
0.6359 |
Remote Similarity |
NPD5514 |
Discontinued |
0.6359 |
Remote Similarity |
NPD5143 |
Clinical (unspecified phase) |
0.6359 |
Remote Similarity |
NPD6063 |
Approved |
0.6358 |
Remote Similarity |
NPD2594 |
Approved |
0.6358 |
Remote Similarity |
NPD2595 |
Approved |
0.6355 |
Remote Similarity |
NPD5041 |
Clinical (unspecified phase) |
0.6355 |
Remote Similarity |
NPD6238 |
Discontinued |
0.6354 |
Remote Similarity |
NPD789 |
Phase 2 |
0.6351
|
Remote Similarity |
NPD4846 |
Phase 2 |